Avelumab and Merkel Cell Carcinoma: Clinical Evidence Review on Causation

Legacy Context: From General Health Communication to Targeted Pharmacovigilance

General health and science communication has long emphasized the importance of understanding how environmental and pharmaceutical exposures may influence disease risk. In the context of cancer, public health messaging often focuses on lifestyle factors, screening, and treatment options, with less attention given to the specific pathways by which certain medications might contribute to disease development. This legacy framework provides a foundation for examining more targeted clinical questions, particularly those involving novel therapeutic agents. One such agent is avelumab, a programmed death-ligand 1 (PD-L1) inhibitor approved for the treatment of Merkel cell carcinoma, a rare but aggressive skin cancer. While avelumab is primarily discussed in terms of its therapeutic benefits, a growing body of clinical evidence raises the question of whether exposure to this drug could be associated with an increased risk of Merkel cell carcinoma causation. This pivot from general health education to a focused occupational exposure concern is critical for clinicians, researchers, and public health professionals who must evaluate the full risk profile of immunomodulatory therapies. The transition requires careful consideration of how avelumab’s mechanism of action—enhancing immune response against tumors—might inadvertently influence tumorigenesis in susceptible individuals. By shifting the discourse from broad health literacy to specific pharmacovigilance, we can better assess the implications of avelumab exposure in both therapeutic and occupational settings.

Bridge Transition: Avelumab as a Therapeutic Agent for Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Avelumab was the first therapeutic agent specifically approved for this indication, and its approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200 (https://pubmed.ncbi.nlm.nih.gov/29799096/). In Part A of that study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Causation Analysis: Clinical Evidence Does Not Support Avelumab as a Cause of Merkel Cell Carcinoma

In the context of causation, avelumab is not a chemical trigger for Merkel cell carcinoma but rather a therapeutic agent used to treat it. The clinical evidence reviewed does not indicate that avelumab causes MCC. Instead, avelumab is administered to patients who already have a diagnosis of MCC. The mechanistic pathway linking avelumab to MCC is one of treatment: avelumab blocks PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells. This mechanism is associated with immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who become refractory to avelumab, alternative treatment options are limited. In Europe, approved systemic therapies for MCC are restricted to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For avelumab-refractory patients, combined ipilimumab plus nivolumab has been investigated. In a multicenter study of the prospective skin cancer registry ADOREG, response rates to PD-1/PD-L1 inhibition in metastatic MCC were up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). In a retrospective study of five patients treated at three academic sites in Germany, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab plus nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study confirmed that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab currently approved by the U.S. Food and Drug Administration for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Risk Context and Safety Communication

From a safety-communication perspective, the timeline between avelumab exposure and documented health outcomes is well-characterized in clinical trials and case reports. The JAVELIN Merkel 200 trial established the efficacy and safety profile of avelumab in metastatic MCC, with objective responses observed in approximately one-third of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune-related adverse events, such as hypercalcaemia due to sarcoidosis, can occur during treatment and are managed with standard interventions like corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the timeline to subsequent therapy with ipilimumab plus nivolumab has been documented in retrospective studies, with responses observed in a subset of patients (https://pubmed.ncbi.nlm.nih.gov/33439294/). In summary, the clinical evidence does not support a causal relationship between avelumab and the development of Merkel cell carcinoma. Rather, avelumab is a treatment for MCC, and its use is associated with immune-related adverse events that are manageable. For affected patients, the clinical interpretation is that avelumab provides a therapeutic option for metastatic MCC, with a well-defined safety profile and established efficacy in a subset of patients. For those who become refractory, alternative immune checkpoint inhibitor combinations may offer benefit.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, clinical evidence does not support a causal relationship between avelumab and the development of Merkel cell carcinoma. Avelumab is a therapeutic agent used to treat MCC, not a cause of it. (https://pubmed.ncbi.nlm.nih.gov/29799096/)

What is the mechanism of action of avelumab in Merkel cell carcinoma?

Avelumab is a PD-L1 inhibitor that enhances the immune system's ability to recognize and attack cancer cells. It is approved for metastatic MCC based on the JAVELIN Merkel 200 trial. (https://pubmed.ncbi.nlm.nih.gov/29799096/)

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.